[go: up one dir, main page]

MX2010001881A - Derivados de piridina como moduladores del receptor s1p1/edg1. - Google Patents

Derivados de piridina como moduladores del receptor s1p1/edg1.

Info

Publication number
MX2010001881A
MX2010001881A MX2010001881A MX2010001881A MX2010001881A MX 2010001881 A MX2010001881 A MX 2010001881A MX 2010001881 A MX2010001881 A MX 2010001881A MX 2010001881 A MX2010001881 A MX 2010001881A MX 2010001881 A MX2010001881 A MX 2010001881A
Authority
MX
Mexico
Prior art keywords
pyridine derivatives
receptor modulators
edg1 receptor
formula
edg1
Prior art date
Application number
MX2010001881A
Other languages
English (en)
Inventor
Beat Steiner
Joerg Velker
Boris Mathys
Claus Mueller
Oliver Nayler
Martin Bolli
Cyrille Lescop
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MX2010001881A publication Critical patent/MX2010001881A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La invención se refiere a derivados de piridina novedosos, su preparación y su utilización como compuestos farmacéuticamente activos. Dichos compuestos actúan particularmente como agentes inmunomoduladores.
MX2010001881A 2007-08-17 2008-08-14 Derivados de piridina como moduladores del receptor s1p1/edg1. MX2010001881A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2007053293 2007-08-17
PCT/IB2008/053269 WO2009024905A1 (en) 2007-08-17 2008-08-14 Pyridine derivatives as s1p1/edg1 receptor modulators

Publications (1)

Publication Number Publication Date
MX2010001881A true MX2010001881A (es) 2010-03-10

Family

ID=40193868

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001881A MX2010001881A (es) 2007-08-17 2008-08-14 Derivados de piridina como moduladores del receptor s1p1/edg1.

Country Status (26)

Country Link
US (1) US8598208B2 (es)
EP (1) EP2195311B1 (es)
JP (1) JP5451614B2 (es)
KR (1) KR101541558B1 (es)
CN (1) CN102648198B (es)
AR (1) AR067977A1 (es)
AT (1) ATE502938T1 (es)
AU (1) AU2008290233B2 (es)
BR (1) BRPI0815190A2 (es)
CA (1) CA2695509A1 (es)
CY (1) CY1111830T1 (es)
DE (1) DE602008005770D1 (es)
DK (1) DK2195311T3 (es)
ES (1) ES2361463T3 (es)
HR (1) HRP20110449T1 (es)
MA (1) MA31703B1 (es)
MX (1) MX2010001881A (es)
MY (1) MY153975A (es)
NZ (1) NZ583957A (es)
PL (1) PL2195311T3 (es)
PT (1) PT2195311E (es)
RU (1) RU2492168C2 (es)
SI (1) SI2195311T1 (es)
TW (1) TWI422373B (es)
WO (1) WO2009024905A1 (es)
ZA (1) ZA201001873B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR062683A1 (es) * 2006-09-07 2008-11-26 Actelion Pharmaceuticals Ltd Compuestos derivados de piridin-4-ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos
DK2069335T3 (da) 2006-09-08 2013-02-18 Actelion Pharmaceuticals Ltd Pyridin-3-ylderivater som immunomoduleringsmidler
CA2667545A1 (en) * 2006-10-25 2008-05-02 Neurosearch A/S Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
EP2125797B1 (en) * 2007-03-16 2014-01-15 Actelion Pharmaceuticals Ltd. Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
EP2252609B1 (en) * 2008-03-07 2013-04-17 Actelion Pharmaceuticals Ltd. Pyridin-2-yl derivatives as immunomodulating agents
HRP20170246T4 (hr) 2008-03-17 2020-02-07 Actelion Pharmaceuticals Ltd. Režim doziranja za selektivni agonist s1p1-receptora
DK2427416T3 (en) * 2009-05-04 2016-06-13 Prometic Pharma Smt Ltd Substituted aromatic compounds, and pharmaceutical uses thereof
SG178042A1 (en) 2009-07-16 2012-03-29 Actelion Pharmaceuticals Ltd Pyridin-4-yl derivatives
SI2665720T1 (sl) 2011-01-19 2015-08-31 Actelion Pharmaceuticals Ltd. Derivati 2-metoksi-piridin-4-ila
EP2844655A1 (en) 2012-05-02 2015-03-11 Lupin Limited Substituted pyridine compounds as crac modulators
JP6322630B2 (ja) 2012-08-17 2018-05-09 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ （２Ｚ，５Ｚ）−５−（３−クロロ−４−（（Ｒ）−２，３−ジヒドロキシプロポキシ）ベンジリデン）−２−（プロピルイミノ）−３−（ｏ−トリル）チアゾリジン−４−オンの製造方法及び前記方法において使用される中間体
ES2649475T3 (es) 2013-03-15 2018-01-12 Idorsia Pharmaceuticals Ltd Derivados de piridin-4-ilo
US10385043B2 (en) 2015-05-20 2019-08-20 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
US10111841B2 (en) 2015-06-19 2018-10-30 University Of South Florida Stabilization of alcohol intoxication-induced cardiovascular instability
WO2017004609A1 (en) 2015-07-02 2017-01-05 Exelixis, Inc. Thiadiazole modulators of s1p and methods of making and using
WO2017004608A1 (en) 2015-07-02 2017-01-05 Exelixis, Inc. Oxadiazole modulators of s1p methods of making and using
WO2017004610A1 (en) 2015-07-02 2017-01-05 Exelixis, Inc. Tercyclic s1p3-sparing, s1p1 receptor agonists
US10508097B2 (en) 2016-03-07 2019-12-17 The Global Alliance For Tb Drug Development, Inc. Antibacterial compounds and uses thereof
BR112018068681A2 (pt) 2016-03-16 2019-01-15 Bayer Cropscience Ag derivados de n-(cianobenzil)-6-(ciclopropil-carbonilamino)-4-(fenil)-piridina-2-carboxamida e compostos relacionados como pesticidas e agentes de proteção de plantas
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US12421194B2 (en) 2020-09-11 2025-09-23 Pi Industries Ltd. Process for the preparation of substituted pyridine compounds and intermediates thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647809A (en) * 1968-04-26 1972-03-07 Chinoin Gyogyszer Es Vegyeszet Certain pyridyl-1 2 4-oxadiazole derivatives
WO1991015583A1 (en) 1990-04-05 1991-10-17 The American National Red Cross A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
JP2002505868A (ja) 1998-03-09 2002-02-26 スミスクライン・ビーチャム・コーポレイション ヒトＥＤＧ−１ｃポリヌクレオチドおよびポリペプチドおよびその使用法
KR100875222B1 (ko) * 1999-08-19 2008-12-19 아스트라제네카 아베 헤테로폴리사이클릭 화합물 및 간접 글루타메이트 수용체길항제로서의 그들의 용도
PL369598A1 (en) 2001-02-21 2005-05-02 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2003062248A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
ATE441654T1 (de) 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
AU2003279915A1 (en) 2002-10-15 2004-05-04 Merck And Co., Inc. Process for making azetidine-3-carboxylic acid
AU2004240586A1 (en) 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
US20070043014A1 (en) * 2003-10-01 2007-02-22 Merck & Co., Inc. 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
US7605171B2 (en) * 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
BRPI0511676A (pt) 2004-05-29 2008-01-08 7Tm Pharma As uso medicinal de ligandos receptores
EP1861359B1 (en) 2005-03-17 2012-11-14 Pfizer Inc. N-(n-sulfonylaminomethyl)cyclopropanecarboxamide derivatives useful for the treatment of pain
AU2006239418A1 (en) 2005-04-26 2006-11-02 Neurosearch A/S Novel oxadiazole derivatives and their medical use
EP1893591A1 (en) 2005-06-08 2008-03-05 Novartis AG POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
CN101203220A (zh) 2005-06-28 2008-06-18 阿斯利康(瑞典)有限公司 新用途
TWI404706B (zh) * 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
DE602007003074D1 (de) * 2006-01-24 2009-12-17 Actelion Pharmaceuticals Ltd Neue pyrinderivate
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
AR062683A1 (es) * 2006-09-07 2008-11-26 Actelion Pharmaceuticals Ltd Compuestos derivados de piridin-4-ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos
DK2069335T3 (da) * 2006-09-08 2013-02-18 Actelion Pharmaceuticals Ltd Pyridin-3-ylderivater som immunomoduleringsmidler
EP2069318B1 (en) * 2006-09-21 2012-09-12 Actelion Pharmaceuticals Ltd. Phenyl derivatives and their use as immunomodulators
AU2007334436A1 (en) 2006-12-15 2008-06-26 Abbott Laboratories Novel oxadiazole compounds
EP2125797B1 (en) * 2007-03-16 2014-01-15 Actelion Pharmaceuticals Ltd. Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
KR20100092473A (ko) * 2007-11-01 2010-08-20 액테리온 파마슈티칼 리미티드 신규한 피리미딘 유도체
US20110046170A1 (en) * 2008-03-06 2011-02-24 Martin Bolli Novel pyrimidine-pyridine derivatives
ES2389042T3 (es) * 2008-03-06 2012-10-22 Actelion Pharmaceuticals Ltd. Compuestos de piridina
EP2252609B1 (en) * 2008-03-07 2013-04-17 Actelion Pharmaceuticals Ltd. Pyridin-2-yl derivatives as immunomodulating agents
AU2009220893A1 (en) * 2008-03-07 2009-09-11 Actelion Pharmaceuticals Ltd Novel aminomethyl benzene derivatives
HUE025984T2 (hu) 2008-05-14 2016-05-30 Scripps Research Inst Szfingozin foszfát receptor új modulátorai
SG178042A1 (en) * 2009-07-16 2012-03-29 Actelion Pharmaceuticals Ltd Pyridin-4-yl derivatives

Also Published As

Publication number Publication date
MY153975A (en) 2015-04-30
AR067977A1 (es) 2009-10-28
TW200918055A (en) 2009-05-01
ES2361463T3 (es) 2011-06-17
TWI422373B (zh) 2014-01-11
WO2009024905A1 (en) 2009-02-26
JP2010536741A (ja) 2010-12-02
AU2008290233B2 (en) 2013-10-10
RU2010109542A (ru) 2011-09-27
RU2492168C2 (ru) 2013-09-10
HK1144809A1 (en) 2011-03-11
HRP20110449T1 (hr) 2011-07-31
EP2195311A1 (en) 2010-06-16
EP2195311B1 (en) 2011-03-23
SI2195311T1 (sl) 2011-07-29
KR20100058561A (ko) 2010-06-03
DK2195311T3 (da) 2011-05-23
ZA201001873B (en) 2012-05-30
CN102648198B (zh) 2015-04-01
AU2008290233A1 (en) 2009-02-26
JP5451614B2 (ja) 2014-03-26
CN102648198A (zh) 2012-08-22
US8598208B2 (en) 2013-12-03
KR101541558B1 (ko) 2015-08-03
BRPI0815190A2 (pt) 2015-03-31
MA31703B1 (fr) 2010-09-01
NZ583957A (en) 2011-09-30
ATE502938T1 (de) 2011-04-15
PL2195311T3 (pl) 2011-08-31
CA2695509A1 (en) 2009-02-26
US20110212998A1 (en) 2011-09-01
CY1111830T1 (el) 2015-10-07
PT2195311E (pt) 2011-05-25
DE602008005770D1 (de) 2011-05-05

Similar Documents

Publication Publication Date Title
MX2010001881A (es) Derivados de piridina como moduladores del receptor s1p1/edg1.
MX2009009597A (es) Derivados de amino-piridina como agonistas del receptor s1p1/edg1.
MY149869A (en) Thiophene derivatives as s1p1/edg1 receptor agonists
WO2009074950A3 (en) Thiophene derivatives as agonists of s1p1/edg1
MX2012000414A (es) Derivados piridin-4-ilo.
ZA200807274B (en) Novel pyridine derivatives
MX2010004576A (es) Derivados de pirimidina novedosos.
MX2010009645A (es) Derivados novedosos de aminometil benceno.
MY153921A (en) Aminopyrazole derivatives
MY150661A (en) Pyridin-3-yl derivatives as immunomodulating agents
MY154909A (en) Novel thiophene derivatives
MY149853A (en) Pyridin-4-yl derivatives as immunomodulating agents
NZ593110A (en) pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
MY153985A (en) Aminotriazole derivatives as alx agonists
TW200700406A (en) Novel thiophene derivatives
TW200942530A (en) Pyridine compounds
TW200716591A (en) Novel thiophene derivatives
TW200708511A (en) Novel thiophene derivatives
TW200716552A (en) Novel thiophene derivatives
TW200738670A (en) Novel thiophene derivatives
MY183039A (en) Pyridin-2-yl derivatives as immunomodulating agents
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
MX2013006420A (es) Derivados de aminotriazol hidrolixado como agonistas del receptor de alx.
TN2012000105A1 (en) Spirolactam derivatives and uses of same
MY152557A (en) 3-aminocyclopentanecarboxamides as chemokine receptor modulators

Legal Events

Date Code Title Description
FG Grant or registration